

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David M. Knight, et al.  
 Serial No. : 09/920,262 Art Unit:  
 Filed : August 1, 2001 Examiner:  
 For : Anti-IL-12 Antibodies, Compositions, Methods And Uses

4/a



I hereby certify that this correspondence is being deposited with the  
 United States Postal Service as first class mail in an envelope addressed  
 to: Commissioner for Patents, Washington, D.C. 20231 on

February 22, 2002

(Date of Deposit)

Guy Kevin Townsend

Name of applicant, assignee, or Registered Representative

(Signature)

February 22, 2002

(Date of Signature)

Commissioner for Patents  
 Washington, D.C. 20231

## RESPONSE

Pursuant to the requirements of 37 CFR 1.822 and/or 1.823 and further to the office action dated October 23, 2001, Applicant submits a corrected copy of the Sequence Listing in computer readable form, including a printed version of the Sequence Listing of the subject application. As required, a copy of the Formalities Letter is also attached.


Furthermore, a Verified Statement concerning the enclosed diskette is submitted herewith.

If any fees are due in connection with the filing of this response, authorization is hereby given to charge the amount of such fee to Deposit Account No. 10-0750/CEN0248/GKT in the name of Johnson & Johnson.

Respectfully submitted,

Guy Kevin Townsend  
 Registration No. 34,033  
 Attorney for Applicants

2/22/02  
 Johnson & Johnson  
 One Johnson & Johnson Plaza  
 New Brunswick, NJ 08933-7003  
 732.524.2517



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. Knight, et al.

Serial No. : 09/920,262

Art Unit:

Filed : August 1, 2001

Examiner:

For : Anti-IL-12 Antibodies, Compositions, Methods And Uses

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Commissioner for Patents, Washington, D.C. 20231 on

February 22, 2002

(Date of Deposit)

Guy Kevin Townsend

Name of applicant, assignee, or Registered Representative

(Signature)

February 22, 2002

(Date of Signature)

Honorable Commissioner for Patents  
Washington, D.C. 20231


**Verified Statement Under 37 CFR §1.821(f)**

I hereby verify that the computer readable diskette enclosed herewith includes the same information as provided in the Sequence Listing of the subject application, and that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of the Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

Guy Kevin Townsend  
Registration No. 34,033  
Attorney for Applicant(s)

2/22/02  
Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
732.524.2517  
Dated: February 22, 2002



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/920,262	08/01/2001	Joi Giles-Komar	CEN0248

CONFIRMATION NO. 5697

000027777

AUDLEY A. CIAMPORCERO JR.  
JOHNSON & JOHNSON  
ONE JOHNSON & JOHNSON PLAZA  
NEW BRUNSWICK, NJ 08933-7003

## FORMALITIES LETTER



\*OC000000006954128\*

Date Mailed: 10/23/2001

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

A copy of this notice **MUST** be returned with the reply.

*Gene*

RECEIVED  
PATENT INFORMATION  
SERVICES

NOV 15 2001

TO FILE REFER TO

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE